Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals SynergyTM, a software solution enhancing collaboration between pharmaceutical and biotechnology sponsors and their contract partners. Signals Synergy aims to streamline processes, improve data stewardship, and reduce errors and delays in project management.
Positive
- None.
New CRO system-level expansion elevates data stewardship and enables organizations to gain more insight with less oversight
Addressing the challenge of relying on email or file-sharing platforms to report complex scientific findings, Signals Synergy expands its Signals Notebook and Signals Research Suite offerings to serve as a data steward and project management layer between sponsors and contract partners. These capabilities enable Signals Synergy to streamline processes, enhance sustainability, and reduce the errors and delays commonly associated with conventional systems.
Kevin Willoe, SVP and general manager of Revvity Signals Software, emphasized the transformative potential of Signals Synergy: "We understand the importance of collaboration and data integrity for our pharma and biotech customers as they work with global contract partners to conduct complex experiments and communicate results. We see Signals Synergy as a driver of digital innovation, merging scientific project management with efficient data sharing into one seamless platform. With Signals Synergy, Revvity Signals is proud to offer the most comprehensive solution on the market, poised to accelerate the pace of drug innovation like never before."
Revvity Signals Software will officially introduce Signals Synergy at the Bio-IT World Conference & Expo, April 15-17, in
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415189154/en/
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com
Source: Revvity
Revvity, Inc. has launched Signals SynergyTM, a software solution designed to facilitate collaboration and data exchange between pharmaceutical and biotechnology sponsors and their contract partners.
Signals Synergy aims to drive greater collaboration, project management, and data exchange between pharmaceutical and biotechnology sponsors and their external contract partners.
Revvity Signals Software will introduce Signals Synergy at the Bio-IT World Conference & Expo in Boston, Massachusetts.
Kevin Willoe is the Senior Vice President and General Manager of Revvity Signals Software.
Revvity Inc.
NYSE:RVTY
RVTY Rankings
#871 Ranked by Market Cap
#3691 Ranked by Stock Gains
#1920 Ranked by Dividends
RVTY Latest News
Apr 4, 2024
Revvity To Hold Earnings Call on Monday, April 29, 2024
Apr 2, 2024
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software
Mar 20, 2024
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
Mar 18, 2024
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
Feb 21, 2024
Revvity to Present at Upcoming Investor Conferences
RVTY Stock Data
About RVTY
as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti